文献速递脑血管病

效用加权改良Rankin量表作为卒中试验主要结局:一项模拟研究

Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study.
PubMed 文献 · Stroke · 2018-03-13

该研究基于MR CLEAN试验中500例患者的数据,在90天时同步评估EuroQol五维自评问卷与改良Rankin量表(mRS),计算各mRS等级的效用权重,并通过模拟评估效用加权mRS(UW-mRS)检测治疗效应的统计效能。结果显示UW-mRS效能(85%)高于二分法(71%)但低于序数法(87%),且未能捕捉个体效用变异。

要点

  • mRS 0至6级平均效用值分别为0.95、0.93、0.83、0.62、0.42、0.11和0。
  • UW-mRS效能85%,高于二分法71%,低于序数法87%。
  • UW-mRS作为主要结局未能捕捉个体效用值变异,可能降低随机试验统计效能。

核心结论

  • UW-mRS作为主要结局未能捕捉个体效用值变异,可能降低随机试验的统计效能。

研究设计与样本

  • 基于MR CLEAN试验中500例患者的数据,在纳入后90天同步评估EuroQol五维自评问卷与mRS,计算各mRS等级的效用权重,并通过模拟评估统计效能。

主要发现

  • mRS 0至6级平均效用值(标准差)分别为0.95(0.08)、0.93(0.13)、0.83(0.21)、0.62(0.27)、0.42(0.28)、0.11(0.28)和0(0)。
  • 各mRS等级内个体患者间效用值变异很大。
  • 模拟治疗效应为优势比1.65(有利于治疗组),对所有mRS截点相似。
  • UW-mRS效能85%,高于二分法71%,低于序数法87%。

关键数值与推荐

  • 模拟治疗效应为优势比1.65,对所有mRS截点相似。
  • 统计效能以10000次模拟中治疗效应达统计学显著(P≤0.05)的比例表示。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The utility-weighted modified Rankin Scale (UW-mRS) has been proposed as a new patient-centered primary outcome in stroke trials. We aimed to describe utility weights for the mRS health states and to evaluate the statistical efficiency of the UW-mRS to detect treatment effects in stroke intervention trials. METHODS: We used data of the 500 patients enrolled in the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Utility values were elicited from the EuroQol Group 5-Dimension Self-Report Questionnaire assessed at 90 days after inclusion, simultaneously with the mRS. Utility weights were determined by averaging the utilities of all patients within each mRS category. We performed simulations to evaluate statistical efficiency. The simulated treatment effect was an odds ratio of 1.65 in favor of the treatment arm, similar for all mRS cutoffs. This treatment effect was analyzed using 3 approaches: linear regression with the UW-mRS as outcome, binary logistic regression with a dichotomized mRS (0-1/2-6, 0-2/3-6, and 0-4/5-6), and proportional odds logistic regression with the ordinal mRS. The statistical power of the 3 approaches was expressed as the proportion of 10 000 simulations that resulted in a statistically significant treatment effect (P≤0.05). RESULTS: The mean utility values (SD) for mRS categories 0 to 6 were: 0.95 (0.08), 0.93 (0.13), 0.83 (0.21), 0.62 (0.27), 0.42 (0.28), 0.11 (0.28), and 0 (0), respectively, but varied substantially between individual patients within each category. The UW-mRS approach was more efficient than the dichotomous approach (power 85% versus 71%) but less efficient than the ordinal approach (power 85% versus 87%). CONCLUSIONS: The UW-mRS as primary outcome does not capture individual variation in utility values and may reduce the statistical power of a randomized trial.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Dijkland SA, Voormolen DC, Venema E, et al. Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study. Stroke. 2018. PMID: 29535271. doi:10.1161/STROKEAHA.117.020194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。